{"id":"W2885300646","doi":"10.1158/1538-7445.am2018-ct167","title":"Abstract CT167: Phase II study of dianhydrogalactitol (VAL-083) in patients with bevacizumab-naive recurrent glioblastoma, MGMT-unmethylated","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Delmar (Canada)","funders":"","keywords":"Temozolomide; Bevacizumab; Medicine; Oncology; Phases of clinical research; Internal medicine; Refractory (planetary science); Cancer research; Clinical trial; Radiation therapy; Chemotherapy; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008318919,0.001340101,0.001833632,0.0003813177,0.0003229118,0.00078998,0.0007760862,0.0008392351,0.00252368],"category_scores_gemma":[0.0005176236,0.0005542054,0.0009522789,0.0003897881,0.0007664991,0.0005610395,0.0002729289,0.002733082,0.0009173917],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001082957,"about_ca_system_score_gemma":0.001744954,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002669177,"about_ca_topic_score_gemma":0.005962544,"domain_scores_codex":[0.9997476,0.00009658846,0.0000144621,0.00005029069,0.00002700645,0.00006408874],"domain_scores_gemma":[0.9996289,0.00003175479,0.00004992005,0.00003109264,0.00003137379,0.000226928],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6025192,0.09375212,0.01005686,0.001229135,0.002176612,0.0006450587,0.0005267201,0.00309273,0.1435843,0.0005369812,0.007784278,0.1340961],"study_design_scores_gemma":[0.3314018,0.6407256,0.0150642,0.00004305415,0.0005819216,0.0004635879,0.0001036145,0.001575581,0.006831434,0.0002125454,0.002955152,0.00004151688],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.994125,0.001748425,0.0003847691,0.0003781203,0.0001333918,0.001237952,0.0008385782,0.0001135751,0.001040033],"genre_scores_gemma":[0.9914303,0.00142754,0.001060121,0.000661438,0.0001141395,0.001123972,0.002252081,0.0000326982,0.001897624],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002669177,"threshold_uncertainty_score":0.008442581,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04938797880228195,"score_gpt":0.417641722004418,"score_spread":0.368253743202136,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}